Back to Atlas
CTransientStandard research/education caution
CMP-0409
Approved in India/selected regions
Ormeloxifene / Centchroman
Endocrine / SERM
Nonhormonal contraceptive and gynecologic positioning
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- SERM
- Primary mechanism
- Tissue-selective estrogen receptor modulation
- Primary market use
- Contraception / gynecology
Pharmacology
- Molecular weight (Da)
- 457.6
- Oral bioavailability
- Oral
- Half-life
- ~1 week; long tissue persistence
- Route tags
- Route-dependent / verify
- Evidence level
- Human/Regional
- Clinical status
- Approved in India/selected regions
- Value-for-money score
- 5 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Regionally important SERM; requires ongoing dosing schedule